Department of Population Sciences, City of Hope, Duarte, California 91010-3000, USA.
Biol Blood Marrow Transplant. 2011 Oct;17(10):1428-35. doi: 10.1016/j.bbmt.2011.07.005. Epub 2011 Jul 18.
Hematopoietic cell transplantation (HCT) is now a curative option for certain categories of patients with hematologic malignancies and other life-threatening illnesses. Technical and supportive care has resulted in survival rates that exceed 70% for those who survive the first 2 years after HCT. However, long-term survivors carry a high burden of morbidity, including endocrinopathies, musculoskeletal disorders, cardiopulmonary compromise, and subsequent malignancies. Understanding the etiologic pathways that lead to specific post-HCT morbidities is critical to developing targeted prevention and intervention strategies. Understanding the molecular underpinnings associated with graft-versus-host disease (GVHD), organ toxicity, relapse, opportunistic infection, and other long-term complications now recognized as health care concerns will have significant impact on translational research aimed at developing novel targeted therapies for controlling chronic GVHD, facilitating tolerance and immune reconstitution, reducing risk of relapse and secondary malignancies, minimizing chronic metabolic disorders, and improving quality of life. However, several methodological challenges exist in achieving these goals; these issues are discussed in detail in this paper.
造血细胞移植(HCT)现在是某些血液系统恶性肿瘤和其他危及生命疾病患者的一种治疗选择。技术和支持性护理使得那些在 HCT 后 2 年内存活的患者的生存率超过 70%。然而,长期幸存者患有多种疾病,包括内分泌疾病、肌肉骨骼疾病、心肺功能障碍和随后的恶性肿瘤。了解导致特定 HCT 后发病率的病因途径对于制定有针对性的预防和干预策略至关重要。了解与移植物抗宿主病(GVHD)、器官毒性、复发、机会性感染和其他长期并发症相关的分子基础,这些并发症现在被认为是医疗保健关注的问题,将对旨在开发新型靶向疗法以控制慢性 GVHD、促进耐受和免疫重建、降低复发和继发性恶性肿瘤风险、最小化慢性代谢紊乱以及提高生活质量的转化研究产生重大影响。然而,在实现这些目标方面存在一些方法学挑战;本文详细讨论了这些问题。